Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles
Abstract
Infections with influenza A virus (IAV) cause high morbidity and mortality in humans. Additional to vaccination, antiviral drugs are a treatment option. Besides FDA-approved drugs such as oseltamivir or zanamivir, virus-derived defective interfering (DI) particles (DIPs) are considered promising new agents. IAV DIPs typically contain a large internal deletion in one of their eight genomic viral RNA (vRNA) segments. Consequently, DIPs miss the genetic information necessary for replication and can usually only propagate by co-infection with infectious standard virus (STV), compensating for their defect. In such a co-infection scenario, DIPs interfere with and suppress STV replication, which constitutes their antiviral potential.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 03, 2021
- Source ID
- 10.1186/s12915-021-01020-5
Entities
People
- Klaus Schughart
- Marc D. Hein
- Michael Winkler
- Pavel Marichal-gallardo
- Prerna Arora
- Sascha Y Kupke
- Stefan Pöhlmann
- Udo Reichl
- Yvonne Genzel
Organizations
- Defense Advanced Research Projects Agency
- Max Planck Institute for Dynamics of Complex Technical Systems